UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group
| Autor: | Y, Hata, J, Uchino, K, Asaishi, Y, Kubo, M, Mito, T, Tanabe, M, Ogita, K, Hirata |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Breast Neoplasms Middle Aged Disease-Free Survival Mitomycins Survival Rate Tamoxifen Treatment Outcome Receptors Estrogen Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Humans Female Neoplasm Recurrence Local Uracil Aged Follow-Up Studies Neoplasm Staging Retrospective Studies Tegafur |
| Zdroj: | Oncology (Williston Park, N.Y.). 13(7 Suppl 3) |
| ISSN: | 0890-9091 |
| Popis: | A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive primary breast cancer. Mitomycin was administered intravenously at 13 mg/m2 on the day of surgery. Patients judged to be ER-positive were randomly allocated to either group A, which received oral tamoxifen 20 mg/day 14 days after surgery for 2 years, or group B, receiving oral UFT 400 mg/day plus tamoxifen 20 mg/day. A total of 219 patients were enrolled in group A, of which 213 (97.3%) were determined to be eligible; 225 patients enrolled in group B and 223 (99.1%) were eligible. The 5-year survival rates were 93.0% for group A and 95.4% for group B, with no significant difference between groups. The 5-year relapse-free survival rates were 83.1% for group A and 90.7% for group B, a significant advantage (P = .020) for the UFT plus tamoxifen group. Combination therapy with mitomycin, tamoxifen, and UFT proved to be an effective postoperative chemoendocrine therapy for stage II, ER-positive breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|